<SUBMISSION>
<ACCESSION-NUMBER>0000950123-10-093953
<TYPE>SC 13D/A
<PUBLIC-DOCUMENT-COUNT>1
<FILING-DATE>20101019
<DATE-OF-FILING-DATE-CHANGE>20101018
<GROUP-MEMBERS>ARTISTRY ACQUISITION CORP.
<SUBJECT-COMPANY>
<COMPANY-DATA>
<CONFORMED-NAME>Abraxis BioScience, Inc.
<CIK>0001409012
<ASSIGNED-SIC>2834
<IRS-NUMBER>300431735
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 13D/A
<ACT>34
<FILE-NUMBER>005-83382
<FILM-NUMBER>101128861
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
<PHONE>310-883-1300
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>11755 WILSHIRE BLVD., 20TH FLOOR
<CITY>LOS ANGELES
<STATE>CA
<ZIP>90025
</MAIL-ADDRESS>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>Abraxis Biosciences, Inc.
<DATE-CHANGED>20071120
</FORMER-COMPANY>
<FORMER-COMPANY>
<FORMER-CONFORMED-NAME>New Abraxis, Inc.
<DATE-CHANGED>20070806
</FORMER-COMPANY>
</SUBJECT-COMPANY>
<FILED-BY>
<COMPANY-DATA>
<CONFORMED-NAME>CELGENE CORP /DE/
<CIK>0000816284
<ASSIGNED-SIC>2834
<IRS-NUMBER>222711928
<STATE-OF-INCORPORATION>DE
<FISCAL-YEAR-END>1231
</COMPANY-DATA>
<FILING-VALUES>
<FORM-TYPE>SC 13D/A
</FILING-VALUES>
<BUSINESS-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
<PHONE>(908)673-9000
</BUSINESS-ADDRESS>
<MAIL-ADDRESS>
<STREET1>86 MORRIS AVENUE
<CITY>SUMMIT
<STATE>NJ
<ZIP>07901
</MAIL-ADDRESS>
</FILED-BY>
<DOCUMENT>
<TYPE>SC 13D/A
<SEQUENCE>1
<FILENAME>y87200sc13dza.htm
<DESCRIPTION>SC 13D/A
<TEXT>
<HTML>
<HEAD>
<TITLE>sc13dza</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="font-size: 1pt; width: 100%; border-bottom: black 2pt solid"> </DIV> <DIV style="font-size: 1pt; width: 100%; border-bottom: black 1pt solid"> </DIV> <P align="center" style="font-size: 14pt"><B>
SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<P align="center" style="font-size: 18pt"><B>SCHEDULE 13D</B>


<DIV align="center" style="font-size: 10pt"><B>(Rule 13d-101)</B>
</DIV>

<P align="center" style="font-size: 12pt"><B>INFORMATION TO BE
INCLUDED IN STATEMENTS FILED PURSUANT TO<BR>RULE 13d-1(a) AND
AMENDMENTS THERETO FILED PURSUANT TO<BR>RULE 13D-2(a)<BR>
(Amendment No.&nbsp;1&nbsp;)*</B>


<DIV align="center">
<DIV style="font-size: 24pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">Abraxis BioScience, Inc.</DIV>
</DIV>


<DIV align="center" style="font-size: 10pt">(Name of Issuer)
</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">Common Stock, $0.001 par value per share</DIV>
</DIV>

<DIV align="center" style="font-size: 10pt">(Title of Class of Securities)
</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000">00383Y102</DIV>
</DIV>

<DIV align="center" style="font-size: 10pt">(CUSIP Number)
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>
Maria Pasquale, Vice President and Chief Legal Counsel<BR>

Celgene Corporation<BR>

86 Morris Avenue<BR>

Summit, New Jersey  07901<BR>

Telephone:  (908) 673-9000</B>
</div>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">
with a copy to:


</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000"><B>
Jonn R. Beeson, Esq.<BR>Kevin B. Espinola, Esq.<BR>Jones Day<BR>3161 Michelson Drive, Suite 800<BR>Irvine, California 92612<BR>Telephone: (949) 851-3939<BR>
</B>
</DIV>
</DIV>


<DIV align="center" style="font-size: 10pt">(Name, Address and Telephone Number of Person<BR> Authorized to
Receive Notices and Communications)
</DIV>


<DIV align="center">
<DIV style="font-size: 10pt; margin-top: 16pt; width: 100%; border-bottom: 1px solid #000000"><B>October
15, 2010</B></DIV>
</DIV>

<DIV align="center" style="font-size: 10pt">(Date of Event Which Requires Filing of this Statement)
</DIV>

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If the filing person has previously filed a statement on Schedule&nbsp;13G to report the acquisition
which is the subject of this Schedule&nbsp;13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box <FONT face="wingdings" size="2">&#111;</FONT>.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Note: </B>Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;* The remainder of this cover page shall be filled out for a reporting person&#146;s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information required on the remainder of this cover
page shall not be deemed to be &#147;filed&#148; for the purpose of Section 18 of the Securities Exchange Act of
1934 (&#147;Act&#148;) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act
(however, <I>see</I> the <I>Notes</I>).


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>

<P align="center" style="font-size: 10pt">
</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P>&nbsp;<DIV style="width: 100%; border: 1px solid black"><DIV align="center">

<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="1" width="100%">
<!-- Begin Table Head --><TR style="font-size: 1px">
<TD width="5%">&nbsp;</TD>
<TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="83%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD valign="middle" align="center"><FONT style="font-size: 18pt"><B>1</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">NAMES OF REPORTING PERSONS<BR>
<BR>
Celgene Corporation</TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;</TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>2</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<BR><BR></TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(a)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#111;</FONT>&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(b)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#254;</FONT>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>3</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SEC USE ONLY</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>4</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SOURCE OF FUNDS (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">WC</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>5</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>6</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CITIZENSHIP OR PLACE OF ORGANIZATION</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">Delaware
</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>7</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">NUMBER OF</TD>
<TD>&nbsp;</TD>
<TD align="left">40,735,300 shares (1)</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">SHARES</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>8</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">BENEFICIALLY</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">OWNED BY</TD>
<TD>&nbsp;</TD>
<TD>0 shares </TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>


<TR valign="bottom">
<TD align="center" colspan="3">EACH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>9</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">REPORTING</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">PERSON</TD>
<TD>&nbsp;</TD>
<TD align="left">40,735,300 shares (1)</TD>
</TR>
<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">WITH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>10</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD align="left">0 shares </TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>11</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">40,735,300 shares (1)</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>12</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)&nbsp;EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT>
</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>13</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">100&#37;</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>14</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CO</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>
</DIV>




<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(1)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Amount represents all the issued and outstanding shares of common stock, par
value $0.001 per share (the &#147;Shares&#148;) of Abraxis
BioScience, Inc. (&#147;Abraxis&#148;) acquired by Celgene Corporation pursuant to the Merger Agreement described in Item 4 below.
</TD>
</TR>
</TABLE>
</DIV>



<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>


<P align="center" style="font-size: 10pt">

2

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="20%">&nbsp;</TD>
<TD width="55%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="9%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->


<TR valign="bottom">
<TD valign="top" nowrap><DIV style="margin-left:0px; text-indent:-0px">CUSIP No.</DIV></TD>
<TD>&nbsp;</TD>
<TD align="center" valign="top"><DIV style="border: 1px solid #000000">00383Y102&nbsp;</DIV></TD>
<TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<P>&nbsp;<DIV style="width: 100%; border: 1px solid black"><DIV align="center">

<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="1" width="100%">
<!-- Begin Table Head --><TR style="font-size: 1px">
<TD width="5%">&nbsp;</TD>
<TD width="1%" style="border-left: 1px solid #000000">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="5%">&nbsp;</TD>
<TD width="1%">&nbsp;</TD>
<TD width="83%">&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
<TD valign="middle" align="center"><FONT style="font-size: 18pt"><B>1</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">NAMES OF REPORTING PERSONS<BR>
<BR>
Artistry Acquisition Corp. </TD>
</TR>
<TR valign="bottom">
<TD>&nbsp;</TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>2</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)<BR><BR></TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(a)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#111;</FONT>&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">(b)&nbsp;&nbsp;&nbsp;<FONT face="wingdings" size="2">&#254;</FONT>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>3</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SEC USE ONLY</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>4</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">SOURCE OF FUNDS (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="11" align="left">AF</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>5</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT></TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>6</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CITIZENSHIP OR PLACE OF ORGANIZATION</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">Delaware
</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>7</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">NUMBER OF</TD>
<TD>&nbsp;</TD>
<TD align="left">Not applicable (2)</TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">SHARES</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>8</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED VOTING POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">BENEFICIALLY</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">OWNED BY</TD>
<TD>&nbsp;</TD>
<TD>Not applicable (2) </TD>
</TR>

<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>


<TR valign="bottom">
<TD align="center" colspan="3">EACH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>9</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SOLE DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">REPORTING</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">PERSON</TD>
<TD>&nbsp;</TD>
<TD align="left">Not applicable (2)</TD>
</TR>
<TR style="font-size: 1px">
<TD colspan="3">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000; border-left: 1px solid #000000; border-right: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
<TD align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD align="center" colspan="3">WITH</TD>
<TD valign="middle" align="center" rowspan="3" style="border-left: 1px solid #000000; border-right: 1px solid #000000"><FONT style="font-size: 18pt"><B>10</B></FONT></TD>
<TD>&nbsp;</TD>
<TD align="left">SHARED DISPOSITIVE POWER</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD align="center" colspan="3">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD align="left">Not applicable (2) </TD>
</TR>
<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>11</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">Not applicable (2)</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>12</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11)&nbsp;EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left"><FONT face="wingdings" size="2">&#111;</FONT>
</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>13</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">Not applicable (2)</TD>
</TR>

<TR style="font-size: 1px">
<TD style="border-top: 1px solid #000000">&nbsp;</TD>
<TD style="border-left: 1px solid #000000; border-top: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom">
<TD valign="middle" align="center" rowspan="3"><FONT style="font-size: 18pt"><B>14</B></FONT></TD>
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">&nbsp;</TD>
</TR>
<TR valign="bottom">
<TD style="border-left: 1px solid #000000">&nbsp;</TD>
<TD colspan="4" align="left">CO</TD>
</TR>
<!-- End Table Body --></TABLE>
</DIV>
</DIV>



<DIV style="margin-top: 3pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">(2)</TD>
    <TD width="1%">&nbsp;</TD>
    <TD> Upon the terms and
subject to the conditions of the Merger Agreement described in Item 4
below, Artistry Acquisition Corp. was merged with and into Abraxis
(the &#147;Merger&#148;) and the separate existence of Artistry Acquisition Corp. ceased.
</TD>
</TR>
</TABLE>
</DIV>





<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>

<DIV style="font-size: 10pt; margin-top: 3pt">
</DIV>


<P align="center" style="font-size: 10pt">

2

</DIV>
<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Amendment No.&nbsp;1 (&#147;Amendment No.&nbsp;1&#148;) amends and supplements the statement on Schedule
13D (the &#147;Schedule&nbsp;13D&#148;) initially filed on July&nbsp;8, 2010 in respect of the Shares. The Schedule&nbsp;13D
remains in effect except to the extent that it is amended, restated or superseded by information
contained in this Amendment No.&nbsp;1. Capitalized terms used and not defined in this Amendment No.&nbsp;1
have the meanings set forth in the Schedule&nbsp;13D.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;3. Source and Amount of Funds or Other Consideration</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The disclosure in Item&nbsp;3 is hereby amended and restated in its entirety to read as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On the terms and subject to the conditions of the Agreement and Plan of Merger (the &#147;Merger
Agreement&#148;), dated as of June&nbsp;30, 2010, by and among Parent, Merger Sub and Abraxis, at the
effective time of the Merger (the &#147;Effective Time&#148;), each Share issued and outstanding immediately
prior to the Effective Time (other than treasury Shares of Abraxis and any Shares owned by Parent,
Merger Sub or any direct or indirect wholly-owned subsidiary of Parent or Abraxis, and any
Dissenting Company Shares (as defined in the Merger Agreement)) was converted into the right to
receive (i)&nbsp;an amount in cash, without interest, equal to $58.00 (the &#147;Cash Consideration&#148;), (ii)
0.2617 of a share of common stock, par value $0.01 per share, of Parent (the &#147;Parent Common
Stock&#148;), and (iii)&nbsp;one contingent value right (&#147;CVR&#148;) issued by Parent subject to and in accordance
with the CVR Agreement described below (collectively, the &#147;Merger Consideration&#148;). No fractional
shares of Parent Common Stock were or will be issued in the Merger, and Abraxis stockholders
received or will receive cash in lieu of any fractional shares of Parent Common Stock.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent used its available cash to pay the Cash Consideration.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References to, and descriptions of, the Merger Agreement as set forth herein are not intended
to be complete and are qualified in their entirety by reference to the Merger Agreement, a copy of
which is filed as Exhibit&nbsp;1 to this Schedule&nbsp;13D and which is incorporated by reference in this
Item&nbsp;3 in its entirety.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;4. Purpose of Transaction</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The disclosure in Item&nbsp;4 is hereby amended and restated in its entirety to read as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The purpose of the Merger Agreement is to acquire control of, and the entire equity interest
in, Abraxis. The purpose of each of the Contingent Value Rights Agreement, the Non-Competition,
Non-Solicitation and Confidentiality Agreement and the Stockholders&#146; Agreement is to facilitate the
transactions contemplated by the Merger Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Merger Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On October&nbsp;15, 2010, Parent completed its acquisition of Abraxis on the terms and subject to
the conditions of the Merger Agreement. The Merger was approved by the stockholders of Abraxis at
a special meeting of the stockholders held on October&nbsp;13, 2010. The Merger became effective on
October&nbsp;15, 2010. As a result of the Merger, Abraxis became a wholly-owned subsidiary of Parent.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As provided in the Merger Agreement, at the Effective Time, each Share issued and outstanding
immediately prior to the Effective Time (other than treasury Shares of Abraxis and any Shares owned
by Parent, Merger Sub or any wholly-owned subsidiary of Parent or Abraxis, and any Dissenting
Company Shares (as defined in the Merger Agreement)) was converted into the right to receive the
Merger Consideration. No fractional shares of Parent Common Stock were issued or will be issued in
the Merger, and Abraxis stockholders received or will receive cash in lieu of any fractional shares
of Parent Common Stock. All outstanding stock options, stock appreciation rights and restricted
stock units of Abraxis were canceled at the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the Merger Agreement, at the Effective Time Merger Sub was merged with and into
Abraxis, with Abraxis continuing as the surviving corporation (the &#147;Surviving Corporation&#148;). The
amended and restated certificate of incorporation of Abraxis, as in effect immediately prior to the
Effective Time, was, by virtue of the Merger, amended and restated in a form mutually agreed and,
as so amended, became the certificate of incorporation of the Surviving Corporation. At the
Effective Time, the by-laws of Merger Sub, as in effect immediately prior to the Effective Time,
became the by-laws of the Surviving Corporation, with such modifications to the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">indemnification provisions as required by Section&nbsp;6.2(a) of the Merger Agreement. The directors of
Merger Sub and the officers of Abraxis in office immediately prior to the Effective Time became the
directors and officers, respectively, of the Surviving Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Following the Merger, the Shares will no longer be traded on the NASDAQ, there will be no
public market for the Shares and the registration of the Shares under the Exchange Act will be
terminated.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Contingent Value Rights Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At the closing of the Merger, Parent and American Stock Transfer &#038; Trust Company, LLC entered
into a Contingent Value Rights Agreement (&#147;CVR Agreement&#148;) governing the terms of the CVRs. A
holder of a CVR is entitled to receive a pro rata portion of cash payments that Parent is obligated
to pay to all holders of CVRs, as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Net Sales Payments</I>. For each full one-year period ending December&nbsp;31 during the
term of the CVR Agreement (a &#147;Net Sales Measuring Period&#148;), a payment that equals (i)
2.5% of that portion of Net Sales of Abraxane&#174; and the other Products (as each such
term is defined in the CVR Agreement) that exceeds $1&nbsp;billion but is less than or equal
to $2&nbsp;billion for such period, plus (ii)&nbsp;an additional amount equal to 5.0% of that
portion of Net Sales of Abraxane&#174; and the other Products that exceeds $2&nbsp;billion but is
less than or equal to $3&nbsp;billion for such period, plus (iii)&nbsp;an additional amount equal
to 10.0% of that portion of Net Sales of Abraxane&#174; and the other Products that exceeds
$3&nbsp;billion for such period; provided that no Net Sales Payments will be due following a
Net Sales Payment Termination Date. &#147;Net Sales Payment Termination Date&#148; is defined as
the last day of the Net Sales Measuring Period ending on December&nbsp;31, 2025; provided
that, if Net Sales of the Products for the Net Sales Measuring Period ending on
December&nbsp;31, 2025 are equal to or greater than $1&nbsp;billion , then the Net Sales Payment
Termination Date will be extended until the earlier of (x)&nbsp;the last day of the Net
Sales Measuring Period during which Net Sales of the Products are less than $1&nbsp;billion
and (y)&nbsp;December&nbsp;31, 2030.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Milestone Payment #1</I>. $250&nbsp;million, with respect to the achievement of U.S.
regulatory approval of Abraxane&#174; for use in the treatment of non-small cell lung
cancer, which permits Parent to market such Product under a label that includes a
progression free survival claim, but only if the foregoing milestone is achieved no
later than the fifth anniversary of the execution of the CVR Agreement.</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="2%" style="background: transparent">&nbsp;</TD>
    <TD width="3%" nowrap align="left"><B>&#149;</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><I>Milestone Payment #2</I>. $400&nbsp;million (if achieved no later than April&nbsp;1, 2013) or
$300&nbsp;million (if achieved after April&nbsp;1, 2013 and before the fifth anniversary of the
CVR Agreement), with respect to the achievement of U.S. regulatory approval of
Abraxane&#174; for use in the treatment of pancreatic cancer, which permits Parent to market
such Product under a label that includes an overall survival claim.</TD>
</TR>

</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent has agreed to use diligent efforts to achieve each of the Milestones above through the
fifth year anniversary of the CVR Agreement and to use diligent efforts to obtain FDA regulatory
approval for the commercial manufacture, marketing and sale of Abraxane&#174; for the treatment of
melanoma, ovarian cancer, bladder cancer and first-line metastatic breast cancer unless the data
generated in an appropriate clinical trial does not support further development of Abraxane&#174; for
the applicable indication. Parent has also agreed to use diligent efforts to sell Abraxane&#174; or any
other Products for which Parent has obtained regulatory approval for the commercial manufacture,
marketing and sale thereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent has agreed to use its reasonable best efforts to cause the CVRs to be approved for
listing for trading on NASDAQ and to maintain such listing for as long as CVRs remain outstanding.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Parent may, at any time on and after the date that fifty percent of the CVRs initially issued
pursuant to the terms of the Merger Agreement either are (i)&nbsp;no longer outstanding, and/or (ii)
repurchased, acquired, redeemed or retired by Parent, redeem all (but not less than all) of the
outstanding CVRs at a cash redemption price equal to the average price paid for all CVRs by Parent
in prior transactions.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Non-Competition, Non-Solicitation and Confidentiality Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As an inducement to Parent and as a condition to Parent entering into the Merger Agreement,
concurrently with the execution of the Merger Agreement, Dr.&nbsp;Patrick Soon-Shiong entered in a
Non-Competition, Non-Solicitation and Confidentiality Agreement with Parent (the &#147;Noncompetition
Agreement&#148;), pursuant to which, among other things, Dr.&nbsp;Soon-Shiong will be generally prohibited,
for 10&nbsp;years from and after the Effective Time, subject to certain exceptions, from owning or
otherwise engaging in the business of researching, developing, licensing, manufacturing, selling,
offering for sale, importing, using, marketing, distributing, practicing or otherwise exploiting
any Albumin-Bound Nab<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Products (as defined in the Noncompetition Agreement) in the United States
and any foreign jurisdiction in which Abraxis was engaged in the business of researching,
developing, licensing, manufacturing, selling, offering for sale, importing, using, marketing,
distributing, practicing or otherwise exploiting any Albumin-Bound Nab<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Products as of the
Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Stockholders&#146; Agreement</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Concurrently with the execution of the Merger Agreement, Dr.&nbsp;Patrick Soon-Shiong and certain
related entities holding, in the aggregate, approximately 82% of the issued and outstanding Shares
(the &#147;Committed Stockholders&#148;) entered in a Stockholders&#146; Agreement with Parent (the &#147;Stockholders&#146;
Agreement&#148;), pursuant to which, among other things, the Committed Stockholders have agreed not to
sell, pledge or otherwise transfer the Parent Common Stock to be acquired by them in the Merger
(the &#147;Merger Common Stock&#148;) for three years following the Effective Time, other than to certain
permitted transferees or in connection with a third party tender or exchange offer, merger or
similar transaction involving Parent; provided that after two years the Committed Stockholders may
sell up to 25% of the aggregate Merger Common Stock held by all Committed Stockholders immediately
after the Effective Time. In addition, the Committed Stockholders have agreed that prior to the
fourth anniversary of the Merger, the Committed Stockholders will not sell, pledge or otherwise
transfer, in any calendar month, in open market transactions, more than 30% of the aggregate Merger
Common Stock held by all Committed Stockholders immediately after the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>General</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other than as described in this Item&nbsp;4, Parent and Merger Sub have no present plans or
proposals that would relate to or result in any of the matters listed in paragraphs (a)&nbsp;through (j)
of Item&nbsp;4 of Schedule&nbsp;13D.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The information set forth, or incorporated by reference, in Items 3, 5 and 6 of this Schedule
13D is hereby incorporated by this reference in this Item&nbsp;4.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;References to, and descriptions of, the Merger Agreement, the CVR Agreement, the
Noncompetition Agreement and the Stockholders&#146; Agreement as set forth herein are not intended to be
complete and are qualified in their entirety by reference to the Merger Agreement, the CVR
Agreement, the Noncompetition Agreement and the Stockholders&#146; Agreement, respectively, copies of
which are filed as Exhibit&nbsp;1, Exhibit&nbsp;2, Exhibit&nbsp;3 and Exhibit&nbsp;4, respectively, to this Schedule
13D and which are incorporated by reference in this Item&nbsp;4 in their entirety.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;5. Interest in Securities of the Issuer</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The disclosure in Item&nbsp;5 is hereby amended and restated in its entirety to read as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&#151; (b)&nbsp;Upon the terms and subject to the conditions of the Merger Agreement and as
described in Item&nbsp;4 hereof, all Shares (other than treasury Shares of Abraxis and any Shares owned
by Parent, Merger Sub or any direct or indirect wholly-owned subsidiary of Parent or Abraxis, and
any Dissenting Company Shares (as defined in the Merger Agreement)) were converted into the right
to receive the Merger Consideration. The Merger was completed and Abraxis became a wholly-owned
subsidiary of Parent on October&nbsp;15, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in this Item&nbsp;5, none of Parent or Merger Sub or, to the knowledge of
Parent or Merger Sub, any of the persons listed on Annex I attached hereto, beneficially owns or
has the power to vote or cause the vote of any Shares.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except for the completion of the Merger, no transactions in Shares were effected by
Parent, Merger Sub or, to the knowledge of Parent or Merger Sub, any of the persons listed on Annex
I attached hereto, during the 60&nbsp;days prior to the date hereof.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&#151; (e)&nbsp;Not applicable.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;7. Material to be Filed as Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Item&nbsp;7 is hereby amended and restated in its entirety to read as follows:
</DIV>

<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">1.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Agreement and Plan of Merger, dated as of June&nbsp;30, 2010, by and among Parent, Merger
Sub and Abraxis (incorporated by reference to Exhibit&nbsp;2.1 to the Current Report on Form 8-K
filed by Parent on July&nbsp;1, 2010).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">2.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Contingent Value Rights Agreement, dated as of October&nbsp;15, 2010, by and between Parent
and American Stock Transfer &#038; Trust Company, LLC (incorporated by reference to Exhibit&nbsp;4.1 to
Form 8-A filed by Parent on October&nbsp;15, 2010).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">3.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Non-Competition, Non-Solicitation and Confidentiality Agreement, dated as of June&nbsp;30, 2010,
by and between Parent and Dr.&nbsp;Patrick Soon-Shiong (incorporated by reference to Exhibit&nbsp;10.3
to the Current Report on Form 8-K filed by Parent on July&nbsp;1, 2010).</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left">4.</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Stockholders&#146; Agreement, dated as of June&nbsp;30, 2010, by and among Parent, Dr.&nbsp;Patrick
Soon-Shiong, California Capital LP, Patrick Soon-Shiong 2009 GRAT 1, Patrick Soon-Shiong 2009
GRAT 2, Michele B. Chan Soon-Shiong GRAT 1, Michele B. Chan Soon-Shiong GRAT 2, Soon-Shiong
Community Property Revocable Trust, California Capital Trust and Michele B. Chan Soon-Shiong
(incorporated by reference to Exhibit&nbsp;10.4 to the Current Report on Form 8-K filed by Parent
on July&nbsp;1, 2010).</TD>
</TR>


</TABLE>
</DIV>
<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="margin-top: 6pt"><TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">



</TABLE>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;After reasonable inquiry and to the best of my knowledge and belief, I certify that the
information set forth in this statement is true, complete and correct.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Celgene Corporation<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Sandesh Mahatme
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Sandesh Mahatme&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Corporate Vice President, Assistant Secretary and Treasurer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>

<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">Artistry Acquisition Corp.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Andre Van Hoek
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Andre Van Hoek&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">President&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt">Dated: October&nbsp;18, 2010
</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ANNEX I</B>
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Annex I is amended and restated in its entirety to read as follows:
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Information Concerning Directors and Executive Officers of Celgene Corporation</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the name, present principal occupation or employment, and
material occupations, positions, offices or employment for at least the past five years of each
director and executive officer of Celgene Corporation. Unless otherwise indicated, all positions
set forth below opposite an individual&#146;s name refer to positions within Celgene. The current
business address of each of these individuals is 86 Morris Avenue, Summit, New Jersey 07901, and
the current business phone number of each of these individuals is (908)&nbsp;673-9000. Each of the
persons listed below is a U.S. citizen.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Board of Directors</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sol J. Barer, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">After the annual meeting of Celgene&#146;s stockholders on
June&nbsp;16, 2010, Dr.&nbsp;Barer transitioned from Chief
Executive Officer to Executive Chairman of the Board
of Directors, a position he will hold until December
31, 2010. Prior to that, Dr.&nbsp;Barer served as
Celgene&#146;s Chief Executive Officer since May&nbsp;1, 2006.
Dr.&nbsp;Barer also served as Celgene&#146;s President from
October&nbsp;1993 to May&nbsp;1, 2006 and as Celgene&#146;s Chief
Operating Officer from March&nbsp;1994 to May&nbsp;1, 2006. Dr.
Barer has served as the Chairman of the Board of
Directors since January&nbsp;2, 2007 and, since March
1994, has served as a director of Celgene. He is also
the Chairman of the Executive Committee of the Board
of Directors. Dr.&nbsp;Barer was Senior Vice
President&#151;Science and Technology and Vice
President/General Manager&#151;Chiral Products from
October&nbsp;1990 to October&nbsp;1993 and Celgene&#146;s Vice
President&#151;Technology from September&nbsp;1987 to October
1990. Dr.&nbsp;Barer received a Ph.D. in organic chemistry
from Rutgers University. Dr.&nbsp;Barer is also a director
of Amicus Therapeutics and serves on the Board of
Trustees of BioNJ and the Board of the Brooklyn
College Foundation. Dr.&nbsp;Barer previously served as
Commissioner of the New Jersey Commission on Science
and Technology.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert J. Hugin
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">After the annual meeting of Celgene&#146;s stockholders on
June&nbsp;16, 2010, Mr.&nbsp;Hugin became Celgene&#146;s new Chief
Executive Officer. Prior to that, Mr.&nbsp;Hugin served
as Celgene&#146;s Chief Operating Officer and President
since May&nbsp;1, 2006. He also served as Celgene&#146;s Senior
Vice President and Chief Financial Officer from June
1999 until May&nbsp;1, 2006. Mr.&nbsp;Hugin has served as a
director of Celgene since December&nbsp;2001. Previously,
Mr.&nbsp;Hugin had been a Managing Director at J.P. Morgan
&#038; Co. Inc., which he joined in 1985. Mr.&nbsp;Hugin
received an A.B. degree from Princeton University and
an M.B.A. from the University of Virginia. Mr.&nbsp;Hugin
is also a director of The Medicines Company, Atlantic
Health System, Inc., a non-profit health care system,
and Family Promise, a national non-profit network
assisting homeless families.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Michael D. Casey
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Casey has served as a director of Celgene since
August&nbsp;2002, is Chairman of the Nominating Committee
and a member of the Executive Committee (since
December&nbsp;2006) and the Management Compensation and
Development Committee (since April&nbsp;2006) of the Board
of Directors. He became Celgene&#146;s lead independent
director in June&nbsp;2007. Mr.&nbsp;Casey was a member of the
Audit Committee from August&nbsp;2002 through December
2006. From September&nbsp;1997 to February&nbsp;2002, Mr.&nbsp;Casey
served as the Chairman, President, Chief Executive
Officer and a director of Matrix Pharmaceutical,</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Inc.
From November&nbsp;1995 to September&nbsp;1997, Mr.&nbsp;Casey was
Executive Vice President at Schein Pharmaceutical,
Inc. In December&nbsp;1996, he was appointed President of
the retail and specialty products division of Schein
Pharmaceutical. From June&nbsp;1993 to November&nbsp;1995, he
served as President and Chief Operating Officer of
Genetic Therapy, Inc. Mr.&nbsp;Casey was President of
McNeil Pharmaceutical (a unit of Johnson &#038; Johnson)
from 1989 to June&nbsp;1993 and Vice President, Sales and
Marketing for Ortho Pharmaceutical Corp. (a
subsidiary of Johnson &#038; Johnson) from 1985 to 1989.
Mr.&nbsp;Casey is also a director of Durect Corp. and AVI
BioPharma, and served as director of Allos
Therapeutics, Inc. through January&nbsp;2010.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Carrie S. Cox
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Ms. Cox was elected to the Board of Directors of
Celgene effective December&nbsp;16, 2009 and is a member
of the Audit Committee (since March&nbsp;2010). Ms.&nbsp;Cox
served as Executive Vice President and President of
Schering-Plough&#146;s Global Pharmaceutical Business
until November&nbsp;3, 2009 when Schering-Plough merged
with Merck &#038; Co., Inc. Prior to joining
Schering-Plough, Ms.&nbsp;Cox served as President of
Pharmacia Corporation&#146;s pharmaceutical business until
its merger with Pfizer Inc. in 2003. Ms.&nbsp;Cox is a
member of the Board of Directors of Texas Instruments
and has served on their audit and compensation
committees, and has recently been appointed to the
Board of Directors of Cardinal Health, Inc. Ms.&nbsp;Cox
is also a member of the Harvard School of Public
Health&#146;s Health Policy and Management Executive
Council and a member of the Board of Overseers of the
University of Pennsylvania Museum of Archaeology and
Anthropology. Ms.&nbsp;Cox is a graduate of the
Massachusetts College of Pharmacy.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Rodman L. Drake
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Drake has served as a director of Celgene since
April&nbsp;2006, is Chairman of the Compensation Committee
since June&nbsp;2007 and a member of the Nominating
Committee of the Board of Directors. Since January
2002, Mr.&nbsp;Drake has been Managing Director of Baringo
Capital LLC, a private equity group he co-founded.
From November&nbsp;1997 to January&nbsp;2002, Mr.&nbsp;Drake was
president of Continuation Investments Group Inc., a
private equity firm. Prior to that, Mr.&nbsp;Drake was
co-chairman of the KMR Power Company and Chief
Executive Officer and Managing Director of Cresap
McCormick and Paget, a leading management consulting
firm, and served as President of the Mandrake Group,
a consulting firm specializing in strategy and
organizational design. He is a member of the boards
of directors of The Student Loan Corporation, Jackson
Hewitt Tax Service, Inc., Crystal River Capital, Inc.
and The Animal Medical Center of New York. He is the
Chairman of the Helios Funds and a Trustee of the
Columbia Atlantic Funds. From 2007 to 2009, Mr.&nbsp;Drake
served as a member of the board of directors of
Golden Minerals Company, formerly Apex Silver Mines
Limited.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Gilla Kaplan, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dr. Kaplan has served as a director of Celgene since
April&nbsp;1998 and is a member of the Audit Committee of
the Board of Directors. Dr.&nbsp;Kaplan is head of the
Laboratory of Mycobacterial Immunity and Pathogenesis
at The Public Health Research Institute Center at the
University of Medicine and Dentistry of New Jersey in
Newark, New Jersey, where she was appointed full
Member in 2002. Dr.&nbsp;Kaplan also was appointed, in
2005, Professor of Medicine at the University of
Medicine and Dentistry of New Jersey. Previously, Dr.
Kaplan was an immunologist in the Laboratory at
Cellular Physiology and Immunology at The Rockefeller
University in New York where she was an Associate
Professor.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">James J. Loughlin
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Loughlin has served as a director of Celgene
since January&nbsp;2007, is Chairman of the Audit
Committee (since June&nbsp;2008) and a member of the</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Compensation Committee (since June&nbsp;2008) of the Board
of Directors. Mr.&nbsp;Loughlin served as the National
Director of the Pharmaceuticals Practice at KPMG LLP,
including a five-year term as member of the Board of
Directors of KPMG. Additionally, Mr.&nbsp;Loughlin served
as Chairman of the Pension and Investment Committee
of the KPMG Board from 1995 through 2001. He also
served as Partner in charge of Human Resources,
Chairman of the Personnel and Professional
Development Committee, Secretary and Trustee of the
Peat Marwick Foundation and a member of the Pension,
Operating and Strategic Planning Committees. In
addition, Mr.&nbsp;Loughlin served as a member of the
Boards of Directors of Alfacell Corporation (until
2008) and Datascope Corp. (until January&nbsp;2009).</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Ernest Mario, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Dr. Mario has served as a director of Celgene since
August&nbsp;2007 and is a member of the Nominating
Committee (since August&nbsp;2007) and the Executive
Committee (since June&nbsp;2008) of the Board of
Directors. Dr.&nbsp;Mario is a former Deputy Chairman and
Chief Executive of Glaxo Holdings plc and a former
Chairman and Chief Executive Officer of ALZA
Corporation. Dr.&nbsp;Mario has been a Director of Boston
Scientific since October&nbsp;2001 and currently is the
Lead Director of Pharmaceutical Product Development.
From 2003 to 2007, he was Chairman and Chief
Executive of Reliant Pharmaceuticals. Dr.&nbsp;Mario
currently is the Chief Executive Officer and Chairman
of Capnia, Inc., a privately held specialty
pharmaceutical company in Palo Alto, CA. A former
Trustee of Duke University, he serves on the Board of
the Duke University Health System. He is Chairman of
the American Foundation for Pharmaceutical Education
and serves as an advisor to the pharmacy schools at
the University of Rhode Island and The Ernest Mario
School of Pharmacy at Rutgers University. Dr.&nbsp;Mario
is the recipient of the 2007 Remington Honor Medal,
which is the highest recognition given by the
American Pharmacists Association.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Walter L. Robb, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Robb has served as a director of Celgene since
1992 and is a member of the Audit Committee of the
Board of Directors. He has been a private consultant
and President of Vantage Management Inc., a
consulting and investor services company, since
January&nbsp;1993. Dr.&nbsp;Robb was Senior Vice President for
Corporate Research and Development of General
Electric Company, and a member of its Corporate
Executive Council from 1986 to December&nbsp;1992. Dr.
Robb is Chairman of the Board of Directors of Capital
District Sports. He also is a director of Mechanical
Technology, Inc., a public company, and several
private companies.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><U><B>Executive Officers</B></U>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" style="border-bottom: 1px solid #000000"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">

<TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sol J. Barer, Ph.D.
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">See information provided above.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Robert J. Hugin
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">See information provided above.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Jacqualyn A. Fouse
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Jacqualyn A. Fouse was appointed Senior Vice
President and Chief Financial Officer of Celgene
effective September&nbsp;27, 2010. Immediately prior
to this appointment, Ms.&nbsp;Fouse served as Chief
Financial Officer of Bunge Limited, a leading
global agribusiness and food company, since July
2007. Prior to joining Bunge, Ms.&nbsp;Fouse served
as Senior Vice President, Chief Financial
Officer and Corporate Strategy at Alcon
Laboratories, Inc. since 2006, and as its Senior
Vice President and Chief Financial Officer since
2002. Ms.&nbsp;Fouse earned a B.A. and an M.A. in
Economics from the University of Texas at
Arlington.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Aart Brouwer
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Brouwer has served as Chairman International
and Senior Advisor to Celgene&#146;s Chairman and
Chief Executive Officer since January&nbsp;1, 2009.
He joined Celgene in November&nbsp;2005.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Graham Burton, MBBS, FRCP
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Burton has served as Senior Vice President
Global Regulatory Affairs, Pharmacovigilance,
Corporate Quality and Compliance since July&nbsp;1,
2003. He joined Celgene in July&nbsp;2003.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Information Concerning Directors and Executive Officers of Artistry Acquisition Corp.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The following table sets forth the name, present principal occupation or employment, and
material occupations, positions, offices or employment for at least the past five years of each
director and executive officer of Artistry Acquisition Corp. Unless otherwise indicated, all
positions set forth below opposite an individual&#146;s name refer to positions within Artistry
Acquisition Corp. The current business address of each of these individuals is 86 Morris Avenue,
Summit, New Jersey 07901, and the current business phone number of each of these individuals is
(908)&nbsp;673-9000. Each of the persons listed below is a U.S. citizen.
</DIV>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="20%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="75%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Present Principal Occupation or Employment;</B></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Name</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Material Positions Held During the Past Five Years</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Perry Karsen
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Karsen has been a director of Artistry Acquisition Corp. since October&nbsp;15, 2010 and serves as its President.</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Andre Van Hoek
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Van Hoek has been a director of Artistry Acquisition
Corp. since June&nbsp;24, 2010 and serves as its Chief Financial Officer.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Sandesh Mahatme
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Mahatme has been a director of Artistry Acquisition
Corp. since June&nbsp;24, 2010 and serves as its Treasurer and
Secretary.</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">Wayne Folkart
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Mr. Folkart has been a director of Artistry Acquisition
Corp. since June&nbsp;24, 2010 and serves as its Vice President&nbsp;-&nbsp;Tax.</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SUBMISSION>
